Combining information from mpMRI and the prostate-specific membrane antigen (PSMA) or 18F- or 11C-Choline PET might offer complementary information in PCa detection, overcoming the limitation of each single technique to identify the entire intraprostatic tumor amount. The gene discussed is FOLH1; the disease is neoplasm.